

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Results of the Phase III COSMIC-311 trial evaluating cabozantinib versus placebo for patients with radioactive iodine (RAI)-refractory or RAI-ineligible locally advanced or metastatic differentiated thyroid cancer demonstrated a significant progression-free survival benefit with cabozantinib in which patient population?**
  - a. Patients whose disease was previously treated with sorafenib or lenvatinib**
  - Patients whose disease was not previously treated with sorafenib or lenvatinib
- 2. Which of the following molecular aberrations is the target of the novel inhibitor larotrectinib?**
  - BRAF V600E mutation
  - b. NTRK fusion**
  - RET fusion
  - RET mutation
- 3. Which of the following agents is a selective RET inhibitor?**
  - Entrectinib
  - Avapritinib
  - c. Pralsetinib**
  - Gilteritinib
- 4. Results from the pivotal LIBRETTO-001 trial assessing selpercatinib demonstrated which of the following outcomes for patients with RET-altered advanced thyroid cancer?**
  - Low response rates and a tolerable safety profile
  - b. High response rates and a tolerable safety profile**
  - High response rates and severe Grade 3 fatigue